Drug · CHEMBL468

THALIDOMIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. THALIDOMIDE. Drugs and targets, record CHEMBL468. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL468

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: THALIDOMIDE; ChEMBL
ChEMBL ID: CHEMBL468; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Kevadon, Talidex, Thalidomide bms (previously thalidomide celgene), Thalidomide lipomed, Thalomid; ChEMBL
Other names: .alpha.-phthalimidoglutarimide, Celgene, Contergan, Distaval, K-17, Myrin, N-phthalylglutamic acid imide, NSC-527179, NSC-66847, Neurosedyn, Pantosediv, Pharmion, Softenon, Talidomida, Thaled; ChEMBL
DrugBank: DB01041; DrugBank
InChIKey: UEJJHQNACJXSKW-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 2 of its 138 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets4

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
CRBN	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase inhibitor	INHIBITOR	https://conductscience.org/library/genes/51185
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase inhibitor	INHIBITOR	https://conductscience.org/library/genes/8451
DDB1	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase inhibitor	INHIBITOR	https://conductscience.org/library/genes/1642
RBX1	CRL4(CRBN) E3 ubiquitin ligase	CRL4(CRBN) E3 ubiquitin ligase inhibitor	INHIBITOR	https://conductscience.org/library/genes/9978

Source ChEMBL

Diseases138

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
plasma cell myeloma	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	144	137	https://conductscience.org/library/drugs?q=MONDO_0009693
hepatocellular carcinoma	Phase 3	ClinicalTrials.gov	17	17	https://conductscience.org/library/drugs?q=MONDO_0007256
prostate cancer	Phase 3	ClinicalTrials.gov	12	12	https://conductscience.org/library/drugs?q=MONDO_0008315
melanoma	Phase 2	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0005105
myelodysplastic syndrome	Phase 3	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0018881
HIV infectious disease	Phase 2	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0005109
glioblastoma	Phase 2	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0018177
non-small cell lung carcinoma	Phase 3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0005233
beta thalassemia	Phase 3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0019402
B-cell chronic lymphocytic leukemia	Phase 2	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0004948

1 to 10 of 138Source Open Targets

See all 138 diseases

Trials393

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02541383	A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma	Phase 3	1,085	2025-04-13	thalidomide	Its name	ClinicalTrials.gov
NCT00075829	Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)	Phase 3	710	2016-08-04	thalidomide	Its name	ClinicalTrials.gov
NCT00083551	UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy	Phase 3	668	2015-09-22	thalidomide	Its name	ClinicalTrials.gov
NCT00004859	Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer	Phase 3	589	2012-03-22	thalidomide	Its name	ClinicalTrials.gov
NCT00507416	Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone	Phase 3	502	2014-05-01	thalidomide	Its name	ClinicalTrials.gov
NCT00098475	Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma	Phase 3	452	2014-01-22	thalidomide	Its name	ClinicalTrials.gov
NCT00049673	Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma	Phase 3	332	2020-10-05	thalidomide	Its name	ClinicalTrials.gov
NCT00602641	Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma	Phase 3	306	2015-06-29	thalidomide	Its name	ClinicalTrials.gov
NCT00081939	UARK 2003-33, Total Therapy III	Phase 2	303	2015-10-21	thalidomide	Its name	ClinicalTrials.gov
NCT00256776	MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation	Phase 3	269	2021-10-18	thalidomide	Its name	ClinicalTrials.gov

1 to 10 of 393

See all 393 trials

Comparisons in its trials58

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm A Part 1 vs Arm B Part 1: Post-Consolidation Stringent Complete Response (sCR) Rate	110 of 542	157 of 543	1,085	NCT02541383	Trial comparisons
Thalidomide vs No Thalidomide: serious adverse events	323 of 323	345 of 345	668	NCT00083551	Trial comparisons
Arm A (Paclitaxel + Carboplatin + Radiation ) vs Arm B (Paclitaxel + Carboplatin + Radiation + Thalidomide): serious adverse events	222 of 289	249 of 288	577	NCT00004859	Trial comparisons
Prednisone vs Observation: deaths from any cause	50 of 165	61 of 163	328	NCT00049673	Trial comparisons
Prednisone vs Observation: serious adverse events	5 of 165	2 of 163	328	NCT00049673	Trial comparisons
MPT-T vs mPR-R: serious adverse events	110 of 148	88 of 150	298	NCT00602641	Trial comparisons
Thal + Dex + Velcade vs Thal + Dex: serious adverse events	58 of 135	45 of 134	269	NCT00256776	Trial comparisons
Thalidomide vs Placebo: The Number of Participants With Adverse Events	117 of 138	98 of 124	262	NCT00004635	Trial comparisons
Thalidomide + Dexamethasone vs DOXIL + Thalidomide + Dexamethasone: Overall Survival: Number of Participants Died Due to Any Cause	21 of 113	22 of 112	225	NCT00097981	Trial comparisons
Thalidomide + Dexamethasone vs DOXIL + Thalidomide + Dexamethasone: Complete Response Rate: Number of Participants Who Achieved a Complete Response	5 of 113	8 of 112	225	NCT00097981	Trial comparisons

1 to 10 of 58

See all 58 comparisons in its trials

Papers from its trials220

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38889735	RESULT	1	PubMed
38014747	RESULT	1	PubMed
37883081	RESULT	1	PubMed
37248485	RESULT	1	PubMed
36699430	RESULT	1	PubMed
36424067	RESULT	1	PubMed
36058507	RESULT	1	PubMed
35745672	RESULT	1	PubMed
35477175	RESULT	2	PubMed
34795208	RESULT	1	PubMed

1 to 10 of 220

See all 220 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL468

GET https://conductscience.org/api/drugs/v1/CHEMBL468/diseases?page=2

API reference For AI assistants